• AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.

• The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (upadacitinib) and Olumiant (baricitinib) in moderate to severe atopic dermatitis.

• Neither provided an updated timeline for the agency's decision.

• Federal regulators are working through safety concerns shrouding Pfizer's JAK inhibitor Xeljanz after a post-marketing study earlier this year turned up risks for dangerous heart side effects and cancer.

• Olumiant, Xeljanz, and Rinvoq already bear boxed warnings about serious infections, blood clots, and cancers.

• As Xeljanz was the first of the class to enter the market, the FDA required Pfizer to conduct a long-term post-marketing study on its product to evaluate those risks further.

• Friday's FDA delay marks the second holdup for Eli Lilly- Incyte Corporation (NASDAQ: INCY) and AbbVie's eczema medicines following an initial setback in April.

• Price Action: LLY stock +0.27% at $232.09, INCY stock -0.94% at $79.25, and ABBV shares +0.44% at $117.69 during the market session on the last check Friday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients

• BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.